All language subtitles for Tomorrows.World.Today.S10E03.1080p.WEB.h264-CBFM_track3_[eng]

af Afrikaans
ak Akan
sq Albanian
am Amharic
ar Arabic
hy Armenian
az Azerbaijani
eu Basque
be Belarusian
bem Bemba
bn Bengali
bh Bihari
bs Bosnian
br Breton
bg Bulgarian
km Cambodian
ca Catalan
ceb Cebuano
chr Cherokee
ny Chichewa
zh-CN Chinese (Simplified)
zh-TW Chinese (Traditional)
co Corsican
hr Croatian
cs Czech
da Danish
nl Dutch
en English
eo Esperanto
et Estonian
ee Ewe
fo Faroese
tl Filipino
fi Finnish
fr French
fy Frisian
gaa Ga
gl Galician
ka Georgian
de German
gn Guarani
gu Gujarati
ht Haitian Creole
ha Hausa
haw Hawaiian
iw Hebrew
hi Hindi
hmn Hmong
hu Hungarian
is Icelandic
ig Igbo
id Indonesian
ia Interlingua
ga Irish
it Italian
ja Japanese
jw Javanese
kn Kannada
kk Kazakh
rw Kinyarwanda
rn Kirundi
kg Kongo
ko Korean
kri Krio (Sierra Leone)
ku Kurdish
ckb Kurdish (Soranî)
ky Kyrgyz
lo Laothian
la Latin
lv Latvian
ln Lingala
lt Lithuanian
loz Lozi
lg Luganda
ach Luo
lb Luxembourgish
mk Macedonian
mg Malagasy
ms Malay
ml Malayalam
mt Maltese
mi Maori
mr Marathi
mfe Mauritian Creole
mo Moldavian
mn Mongolian
my Myanmar (Burmese)
sr-ME Montenegrin
ne Nepali
pcm Nigerian Pidgin
nso Northern Sotho
no Norwegian
nn Norwegian (Nynorsk)
oc Occitan
or Oriya
om Oromo
ps Pashto
fa Persian
pl Polish
pt-BR Portuguese (Brazil)
pt Portuguese (Portugal)
pa Punjabi
qu Quechua
ro Romanian
rm Romansh
nyn Runyakitara
ru Russian
sm Samoan
gd Scots Gaelic
sr Serbian
sh Serbo-Croatian
st Sesotho
tn Setswana
crs Seychellois Creole
sn Shona
sd Sindhi
si Sinhalese
sk Slovak
sl Slovenian
so Somali
es Spanish
es-419 Spanish (Latin American)
su Sundanese
sw Swahili
sv Swedish
tg Tajik
ta Tamil
tt Tatar
te Telugu
th Thai
ti Tigrinya
to Tonga
lua Tshiluba
tum Tumbuka
tr Turkish
tk Turkmen
tw Twi
ug Uighur
uk Ukrainian
ur Urdu
uz Uzbek
vi Vietnamese
cy Welsh
wo Wolof
xh Xhosa
yi Yiddish
yo Yoruba
zu Zulu

Original subtitles

[narrator] On "Tomorrow's World Today," we explore the cutting edge

advances that are shaping four different worlds.

The world of inspiration, where the wonders

of the natural world amaze and inspire us.

The world of creation, where ideas come to life

from traditional arts.

The world of innovation, where ideas and inventions

move us all forward.

The world of production, where innovations are mass produced

to improve our lives.

From Inventionland, World Headquarters,

here's your host, George Davison.

Did you know that your body's constantly writing

a hidden history?

Every day, billions of your cells are shedding

tiny fragments of their DNA into your bloodstream.

It's a molecular code of who you are.

Welcome to "Tomorrow's World Today."

Now, for centuries, this code was invisible to us,

a secret written in a language we simply couldn't see.

The quest to see cancer, well, it all began

in ancient Egypt,

where Edwin Smith Papyrus first described

bulging tumors nearly 5,000 years ago.

But for most of history, we could only find cancer

once it was large enough to feel.

Now that changed in 1928, when Dr. Papanikoláou,

he developed the Pap smear to detect cancer

at the cellular level for the first time.

And he proved that if we could see the change early enough,

we could change the outcome.

Now by the 1960s, imaging techniques

such as mammography, well, it allowed us

to see what the human eye couldn't see.

But even then, we were looking for masses.

The real turning point, it arrived when we stopped

looking for the lump and started looking

for the signal.

We realized that cancer actually leaves microscopic

fingerprints in our blood long before a physical mass

ever appears.

Now today, we're moving beyond just scanning the body.

We're sequencing our survival.

We're entering an era where a simple blood draw can reveal

the earliest signals of many types of cancer.

So I wanna learn more about this.

And I'm gonna send Greg to the World of Innovation

in Madison, Wisconsin, to show us

the latest advancements in cancer screening.

♪♪

For decades, one of the primary goals of modern medicine

has been to find a cure for cancer.

While there are many different types of cancer,

what they have in common is that very often

successful treatment comes down to one thing, early detection.

And that's why we're here in Madison, Wisconsin,

to meet with the makers of the Cancerguard test.

And together, we'll explore how they're helping to win

the battle against this disease today and in tomorrow's world.

I sat down with Dr. Beer, Chief Medical Officer

for Multi-Cancer Early Detection at Abbott Cancer Diagnostics,

to explore their blood test, which uses DNA biomarkers

to screen for multiple cancers.

Dr. Beer, tell me about what was the impetus for developing

Cancerguard as a test? What was the need for that?

Well, first of all, we know that when we detect

cancers earlier, people have better outcomes,

a higher probability of curative therapy,

less aggressive treatment necessary.

But today, we only screen for four or five common cancers.

And so about 70% of cancer diagnoses

and 70% of cancer deaths are due to cancers that

we don't have any screening tests for.

That's the reason for developing Cancerguard.

Why did it take so long for us to get to this point?

I mean, you know, there's been so much advancement

in cancer care and oncology.

Why did it take this long to get to this point?

Well, for a long time, the field has focused

on developing single cancer screening tests.

And it takes a decade or two to develop the evidence necessary

to prove that these tests are useful.

But focusing one cancer at a time has an inherent

limitation once you get beyond the most common cancers.

And so it's really been impossible to address

those other cancers like pancreatic cancer,

ovarian cancer, and others

until we developed a multi cancer approach

like Cancerguard.

Right, so multi cancer early detection is really what

Cancerguard is all about. But the story

that it's looking for is actually in the blood.

Yeah, so it turns out that cancers secrete

into the bloodstream what we call biomarkers,

or minute concentrations of cancer DNA

or cancer associated proteins.

Those are the kinds of markers that we look for in the blood

with Cancerguard, and we put together

these multiple measurements into a single algorithm

that tells us whether we should be concerned

about a cancer or not.

-OK, so the blood basically tells the story in this. -Yes.

So a lot of folks would probably compare this a bit

with Cologuard, which is

an at-home screening for colon cancer.

But rather than making a sample at home and sending it in,

this is a -- this is a blood draw.

Yes, I think there are some similarities and lessons

from Cologuard, but also some differences.

Cologuard proved to us that we can use,

um, uh...

the detection of DNA biomarkers to pick up a cancer early.

That's a critical advance.

But the difference is that Cancerguard is a blood test.

So it's not an at-home stool test like Cologuard.

You can get your blood drawn at home

with what we call mobile phlebotomy,

or a person who can draw your blood,

they can come to your home.

You can also get that at a brick and mortar laboratory

or in a doctor's clinic or a hospital.

Great, well,

now a Cancerguard itself, so it's --

it's not a diagnosis.

It doesn't necessarily mean that you have cancer, but it is

a screening that will let you know that you should talk

to your doctor further. -Yeah.

So just like other screening tests that you can think about,

Cologuard, we've already talked about,

mammography and so on and so forth,

Cancerguard gives a signal

um, that triggers us to

uh...

look and determine whether a cancer's present or not.

So most of the time, one can expect a negative result,

meaning no further workup is necessary.

But when we get a positive result that is not

a diagnosis of cancer,

it is a signal that we need to do more to rule in or rule out

the presence of cancer.

Right, so mammographies and things like this,

this is not to take that place. -No.

Mammography, colorectal cancer screening, lung cancer

screening, if you're a smoker, cervical cancer screening,

perhaps PSA testing are really well established,

proven screening approaches.

And Cancerguard is designed to work in concert with those,

not as a replacement. -Great.

Well, doctor, thank you very much.

Don't go too far, we're gonna catch up again later.

My pleasure. Thank you so much.

♪♪

[Greg] I'm going to meet with Dr. Michelle Beidelschies,

Director of Medical Affairs for Multi-Cancer Early Detection,

to discuss a positive result and care navigation services.

So, doctor, who are the folks that the Cancerguard test

is really designed for?

Yeah, the test is indicated for individuals,

adults, who have not had a prior history of cancer

in the previous three years.

Now, certainly there are risk factors, if you will,

or perhaps even a family history that someone might have.

They may have known genetic predisposition or may not know

their genetic predisposition, but the Cancerguard test

could be right for them.

So a family history isn't necessarily an indicator

of genetic predisposition, as you say.

That's -- that's correct.

A lot of people don't know their family history,

but certainly they have relatives and know

of different cancers that have popped up in their family,

so this technology might be valuable to them.

Right, right. Well, let's kind of walk

through the test itself.

Take me through the process.

So as it relates to getting the Cancerguard test,

it can be ordered by your provider

or you can request it to be ordered through our website.

So it still needs to be

prescribed by a medical provider?

Yes, it needs to be prescribed by a medical provider.

And once that's done, then you get a kit

and you're able to take it to a blood draw station.

We actually have phlebotomists that can come to your home

and actually collect the blood.

And so once that's done, the blood then goes

to the laboratory where the assays are performed,

and then a patient is given a final report.

♪♪

OK, well, let's talk about those results.

What if you get a negative result?

So the negative result is actually quite valuable, right?

That means that there's no cancer signal detected,

which is a great thing.

Now, certainly, there might be situations where

there is a cancer, but the test missed it.

But overall, a no cancer signal detected is a very good thing.

Well, let's look at the opposite as well.

How about if a patient gets a positive result?

Yeah, so if there is a positive result,

we call that a cancer signal detected.

And what that means is that our assay picked up some

of the biological biomarkers in the blood.

Now, this certainly is not diagnostic.

It doesn't necessarily mean you have cancer.

What it means is the assay picked up a signal,

and so it requires further workup to what we call localize

and potentially diagnose a cancer if it in fact exists.

[Greg] Excellent, well,

let's talk a little bit about the blood itself.

What are the things that the Cancerguard test is

looking for in that sample?

So the Cancerguard test is the only test that looks

at a multi-biomarker class approach.

And what that means is we evaluate

two different biomarker classes.

That would be circulating tumor DNA as well as proteins.

And those two biomarker classes are important because this is

what is released from the cancer tumor cells.

And we're able to pick that up as part of our assay.

And what we do is we look at each of those biomarker

classes individually, and then we combine them

together through an algorithm and are able to provide

that result of no cancer signal detected

or cancer signal detected.

So once that positive result comes back,

what other sorts of supports are available

through the Cancerguard network?

Yeah, once you do get a positive result,

we provide care navigation, not just to the patient

but also to the provider.

And so from the provider perspective, we're available

to answer any questions that they might have,

provide educational support.

We have a fantastic field medical team

and the laboratory director that's there

to answer questions.

And then from a patient perspective,

we have a dedicated team of individuals that are able

to support the patient along their journey, whether that's

talking to their insurance company, helping them to get

to imaging needed to localize and diagnose

that potential cancer.

But I think one of the most important assets that we offer

for the patients and support is

the patient reimbursement program

for imaging services.

So we offer up to $6,000 to the patient

for non-covered imaging costs. -Wow, that's really excellent!

Well, doctor, thank you very much.

Thank you.

♪♪

[Greg] I reconnected with Dr. Tom Beer to examine the significant

economic impact of early cancer detection.

Doctor, let's talk about the economic advantage

of a -- of an early detection versus the long-term impact

of a later diagnosis.

Yeah, so we know that treatment of earlier stages

of cancer is not only more straightforward

and often more successful,

but it is usually much less expensive

than treatment for advanced cancer,

especially when the cancer gets to stage four,

where often multiple treatments are required

with very expensive agents.

Now, Cancerguard currently is still a self-pay test,

um, but if you maybe have concerns over family history

or maybe where you were working, it still seems as though

it would be an investment in your long-term health.

Yes, as you mentioned, Cancerguard is available today

as a self-pay test.

Our long-term goal is to have the test be FDA-approved,

widely available, and reimbursed by insurance

so that everyone can access it.

In the meantime, we wanted to make the test available

as soon as possible to as many people as we can.

And we're also learning a great deal by having the test

available to people today. -Excellent.

Well, doctor, again, thank you very much.

Thank you.

[Greg] I had a chance to meet with Allison Barry,

a Cancerguard employee, to discuss her journey

after receiving a positive test result.

-Hi, Allison. -Hi, Greg.

-How are you? -I'm great.

-How are you? -I'm doing well.

So, Allison, you work for the company, but you also have

a really personal connection to the Cancerguard test.

-Tell me about that. -Sure.

So I've been working for the company

for a little over five years.

What brought me to the company was the Cancerguard test

when it was still in development.

I work on communications for the company

and for the test.

So the first day it was available,

I was really excited to order it.

I wanted to know what it was like, the whole process,

so I could go out and talk about it confidently.

I never expected the result to be a positive,

but in fact, it was. -Wow.

What's the next step after you get that positive result?

Sure. So a positive test result

doesn't automatically mean that you have cancer.

You need to follow up with your primary care physician.

And that's exactly what I did a few days later.

And at that appointment, my physician ordered

a set of three CT scans, one of my neck, one of my chest,

and one of my abdomen and my pelvis.

When those test results came back,

they revealed a 22-centimeter likely malignant tumor

on my right ovary.

Wow. So did you have to

immediately undergo surgery? -I did.

I was scheduled for surgery pretty quickly afterward,

and it was a five-hour surgery.

They were able to remove the entire tumor.

They did dozens of biopsies. Those all came back negative.

And the final pathology revealed a stage one

ovarian cancer. -Wow.

So did you have to do any follow-up chemo,

radiation, anything like that? -I did not.

And I was very fortunate in the fact that

my specific type of ovarian cancer is very rare,

and it's known to be resistant to chemotherapy.

So finding it in an early stage was really, really important

for me to just move forward with my life.

Right, it would have been much more difficult

to deal with later on. -Very much so.

Wow. OK.

Well, so now you're doing well. You're cancer-free.

-I am. -Excellent.

Excellent. Well, show me how you signed up

for the test and how somebody can just get online

and take care of this for themselves.

Sure. Yeah.

You just go right to cancerguard.com.

It's really easy.

You can go on a computer, you can go on your phone,

and you just hit, "Request online."

You answer a few questions, you put in your information,

and it goes to a medical professional to review.

And you can also go see your primary care physician

at your next appointment, request the test there.

-So it's really easy. -Excellent.

So it's like signing up for just about

any other website that you find.

-It sure is, yeah. -All right, excellent, well,

Allison, thank you very much. -Thank you so much, Greg.

[George] I'm meeting with David Harding, Senior Vice President

of Pipeline Product Management, to talk about the future

of cancer screenings.

Hi, David. Welcome to Inventionland.

Thank you very much.

It's a pleasure to be here, George.

You know, I'm excited for you to be here

because this field of cancer

and trying to identify cancer earlier,

that's of interest to me. And I --

That, like, even the whole history of cancer, you know,

back in the old days, you'd see a lump,

maybe touch that and know you have a problem.

And then, of course, innovation happens

and screening was invented, and mammography became a thing.

And now we've moved again into the future where now

we're looking at the blood and it's starting to indicate

that we may or may not have a cancer, but being able

to find that out so early,

that's a really important piece of work.

Can you talk a little bit about it?

Yeah, I mean, it really is interesting to look at the arc

of how cancer screening has evolved over the decades.

And I think we're at a fundamental transition point

here where now that we can understand molecularly what's

happening in the blood and get these very small, tiny signals

from cancers that may be in your body,

we have the ability to really revolutionize cancer screening

and change it in a way that's fundamentally different.

That's exciting to me.

And the way I'd like to think about it is it's like

all innovations and technologies.

When they first come out, you know, they can be a little

unnerving, you know, "Should I, should I give that a try?"

And, uh, so I was thinking about how do we get across

to the audience out there that this could be a better way of,

you know, identifying whether or not you may have

cancer, right? -Yeah.

I think it's important to acknowledge that, yes,

there is a certain amount of anxiety that comes

with any kind of medical testing, but then I think

you need to think about the impact

of what this might do.

All of us have friends and family members who

have been detected with late stage cancer.

And we all know the pain and suffering and cost

that comes with that... -[George] Mm-hmm.

...to not only the patient, but also to their family.

And I think you need to really understand that detecting

that cancer early makes a massive difference

in the life of that patient and the family.

And so I think we need to think about what's possible, right?

And be courageous and move forward

with this kind of testing that can fundamentally

expand the number of cancers that we can detect

and potentially detect them much earlier

when there's a chance to treat them much more effectively.

So that's what gives me the courage to move forward

and what I would encourage everybody to think about

as they adopt this new technology.

Yeah, and so trying to get the general population

to understand that this is a big advance

and that they should take a chance

and go get this done.

But I think there's another, there's always like a step

in the process of getting innovations

and technology to market.

So how do we get doctors informed so that,

you know, they're more apt to adopt what's going on here?

I mean, what kind of things would you run into

in the field?

Yeah, typically what I would say is, doctor, have you ever

had a patient come in who was worried about something like,

you know, a pancreatic cancer or ovarian cancer,

these very aggressive, you know, very high-mortality cancers,

have they ever asked you, like, what can I do?

I'm doing all my other screening tests.

What can I do to, you know,

maybe detect those cancers earlier?

And now we have a solution for that, right?

It's a very revolutionary solution that really broadens

the tools that you have, doc, available... -[George] Right.

...to help screen that patient.

And I think most doctors really understand that

very intuitively. -Yeah.

I mean, it's great.

You guys are chasing a noble cause.

David, thanks for everything

you and your team have been working on.

Well, everybody, that's another edition

of "Tomorrow's World Today." And we'll see you next time.

So, David, I've got this new stuff

we're working on in the lab.

And remember, Tomorrow's World is where inspiration

and creation drive innovation and production.

See you next time.

Can't find what you're looking for?
Get subtitles in any language from opensubtitles.com, and translate them here.